Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

× No keyword cloud information.

20 in total

Review 1. Clinical and economic outcomes assessment with myocardial contrast echocardiography.

Authors: L J Shaw; M J Monaghan; P Nihoyannopolous
Journal: Heart Date: 1999-11 Impact factor: 5.994

Review 2. Myocardial perfusion scintigraphy and cost effectiveness of diagnosis and management of coronary heart disease.

Authors: S R Underwood; L J Shaw; C Anagnostopoulos; M Cerqueira; P J Ell; J Flint; M Harbinson; A Kelion; A Al Mohammad; E M Prvulovich
Journal: Heart Date: 2004-08 Impact factor: 5.994

3. Screening asymptomatic low-risk individuals for coronary heart disease: issues and controversies.

Authors: Leslee J Shaw; Roger S Blumenthal; Paolo Raggi
Journal: J Nucl Cardiol Date: 2004 Jul-Aug Impact factor: 5.952

Review 4. Epidemiologic guidance with coronary artery calcium scoring.

Authors: Paolo Raggi; Leslee J Shaw
Journal: Curr Cardiol Rep Date: 2008-02 Impact factor: 2.931

5. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Authors: Olof Johnell; Bengt Jönsson; Linus Jönsson; Dennis Black
Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981

6. [Cost-effectiveness of prevention of coronary disease in Germany].

Authors: K W Lauterbach; A Gerber; G Klever-Deichert; B Stollenwerk
Journal: Z Kardiol Date: 2005

7. Risk-sensitive therapeutic strategies for coronary artery disease: toward testing-driven therapy in stable angina patients with low-to-intermediate risk cardiac imaging results.

Authors: D D Miller; B J Gersh
Journal: J Nucl Cardiol Date: 1997 Sep-Oct Impact factor: 5.952

Review 8. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Authors: A J Coukell; M I Wilde
Journal: Pharmacoeconomics Date: 1998-08 Impact factor: 4.981

Review 9. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.

Authors: K L Goa; L B Barradell; D McTavish
Journal: Pharmacoeconomics Date: 1997-01 Impact factor: 4.981

Review 10. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Authors: Kurt Neeser; Georg Lübben; Uwe Siebert; Wendelin Schramm
Journal: Pharmacoeconomics Date: 2004 Impact factor: 4.981